A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve subjects with follicular lymphoma.

Site located at Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center.

Location: 181 S. Buena Vista St. , Burbank, CA 91505

For more information contact us at DFCC_Clinical_Research@providence.org or call (818) 748-4793

Participate in a Clinical Trial

Learn More